|
|
 | | | |
- close
- close
- close
- close
StreetInsider.com
May 8
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Arqule%2C+Inc.+%28ARQL%29+Posts+Q1+Loss+of+9cShare/8315641.html for the full story.
FierceBiotech
Apr 1
Comment
After a pair of trial setbacks with a separate program from ArQule, Japan-based drugmaker Daiichi Sankyo has decided to jettison an alliance with the Woburn, MA-based drug developer on an early-stage compound known as ARQ 092. ArQule ($ARQL)...
Benzinga
Apr 1
Comment
ArQule (NASDAQ: ARQL) today announced it has regained worldwide rights for the development and commercialization of compounds covered under its AKT collaboration with Daiichi Sankyo Co., Ltd., including the lead compound emerging from this...
StreetInsider.com
Mar 14
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Arqule%2C+Inc.+%28ARQL%29+Tops+Q4+EPS+by+4c%3B+Guides+FY13+Net+Loss/8184085.html for the full story.
Stock Blog Hub
Jan 16
Comment
ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with Pfizer’s (PFE)...
StreetInsider.com
Jan 11
Comment
Unwired Planet, Inc. (NASDAQ: UPIP) 29% HIGHER; announced that it has entered into a patent purchase agreement with Ericsson (NASDAQ: ERIC) whereby Ericsson will transfer to Unwired Planet 2,185 issued US and international patents and patent...
Wall Street Journal
Jan 11
Comment
Among the companies with shares expected to actively trade in Friday's session are Best Buy, ArQule and Dendreon.
FierceBiotech
Jan 11
Comment
ArQule ($ARQL) suffered another failure with its top anti-cancer contender tivantinib. This time the experimental kinase inhibitor fell short in a midstage study in patients with aggressive cases of colorectal cancer, a fresh setback in a program...
Benzinga
Jan 11
Comment
Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq: ARQL) today announced the top-line results of a randomized Phase 2
signal generation trial of tivantinib (ARQ 197) used in combination with
irinotecan and cetuximab...
StreetInsider.com
Jan 11
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Daiichi%2C+ArQule+%28ARQL%29+Report+ARQ+197+Missed+Endpoint+in+Phase+2/8002337.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
